The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Daiichi Sankyo; Gilead Sciences; Novartis; Roche
Travel, Accommodations, Expenses - Daiichi Sankyo; Pfizer; Roche
Prevention of sacituzumab govitecan (SG)-related neutropenia and diarrhea in patients (pts) with triple-negative or HR+/HER2- advanced breast cancer (ABC; PRIMED): A phase 2 trial.
 
José Manuel Pérez García
Employment - MedSIR
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Lilly; Roche; Seagen
Travel, Accommodations, Expenses - Roche
 
María Gión
No Relationships to Disclose
 
Manuel Ruiz-Borrego
Honoraria - Novartis; pfizer; Roche/Genentech
Consulting or Advisory Role - Puma Biotechnology; Roche
 
Isabel Blancas
Honoraria - AstraZeneca Spain; Bristol Myers Squibb; Daiichi Sankyo/Astra Zeneca; Eisai; Gilead Sciences; GlaxoSmithKline; Grunenthal; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; Veracyte; Veracyte
Consulting or Advisory Role - AstraZeneca Spain; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Eisai; Lilly; Novartis; Pfizer; Pierre Fabre; Roche; Veracyte
Research Funding - Agendia (Inst); AstraZeneca Spain (Inst); Lilly; Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Gilead Sciences; Lilly; Novartis; Pfizer; Pierre Fabre; Roche
Other Relationship - Fundación San Juan de Dios; Medical Science Innovation Research (MEDSIR)
 
Elena Lopez-Miranda
Honoraria - AstraZeneca; Daiichi Sankyo; Lilly
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Lilly
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Gilead Sciences; Novartis; Roche
 
Salvador Blanch
No Relationships to Disclose
 
Sabela Recalde
Speakers' Bureau - AstraZeneca Spain; Lilly
Travel, Accommodations, Expenses - AstraZeneca Spain; Roche
 
Lourdes Calvo
No Relationships to Disclose
 
Xavier Gonzalez
Expert Testimony - Novartis; Pierre Fabre
Travel, Accommodations, Expenses - AstraZeneca
 
Nerea Ancizar
No Relationships to Disclose
 
Serafin Morales Murillo
No Relationships to Disclose
 
Patricia Cortez
No Relationships to Disclose
 
Javier Cardona
Employment - MedSIR
 
Eileen Shimizu
Employment - MedSIR
 
José Antonio Guerrero
Employment - MedSIR
 
Miguel Sampayo-Cordero
Employment - MedSIR
 
Alejandro Martinez-Bueno
Honoraria - AstraZeneca; GlaxoSmithKline; Seagen
Travel, Accommodations, Expenses - GlaxoSmithKline; Roche
 
Javier Cortes
Stock and Other Ownership Interests - Leuko (I); MAJ3 Capital
Honoraria - AstraZeneca; Celgene; Daiichi Sankyo; Eisai; Gilead Sciences; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Samsung; Steamline Therapeutics
Consulting or Advisory Role - Abbvie; AstraZeneca; Athenex; Bioasis; Biocon; Bioinvent; BioNTech SE; Boehringer Ingelheim; Bridgebio; Celgene; Cellestia Biotech; Clovis Oncology; Daiichi Sankyo; Ellipses Pharma; ERYTECH Pharma; Expres2ion Biotechnologies; GEMoaB; Gilead Sciences; GlaxoSmithKline; HiberCell; Jazz Pharmaceuticals; Leuko; Lilly; Menarini; Merck Sharp & Dohme; Polyphor; Reveal Genomics; Roche; Seagen; SERVIER; Zymeworks
Research Funding - ARIAD (Inst); Astrazeneca (Inst); Baxalta (Inst); Bayer (Inst); Eisai (Inst); Guardant Health (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Piqur (Inst); Puma Biotechnology (Inst); Queen Mary university of London (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy.Aleix Prat, Antonio Llombart, Javier Cortés.US 2019/ 0338368 A1; Pharmaceutical Combinations of A Pi3k Inhibitor And A Microtubule Destabilizing Agent. Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizalde. WO 2014/199294 A.
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Merck Sharp&Dhome; Novartis; Pfizer; Roche; Steamline Therapeutics
 
Antonio Llombart-Cussac
Leadership - MedSIR
Stock and Other Ownership Interests - Initia-Research; MAJ3 Capital
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Roche
Speakers' Bureau - AstraZeneca; Lilly; Merck Sharp & Dohme; Novartis; Pfizer
Research Funding - Agendia; Daiichi Sankyo; Gilead Sciences; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche
Patents, Royalties, Other Intellectual Property - US 2019/ 0338368 A1
Travel, Accommodations, Expenses - AstraZeneca; Merck Sharp & Dohme; Pfizer; Roche; Stemline Therapeutics